The phosphoinositide3-kinase (PI3K)/Akt and downstream mammalian target of rapamycin complex 1 (mTORC1) signalling cascades promote normal growth and are frequently hyperactivated in tumour cells. mTORC1 is also regulated by local nutrients, particularly amino acids, but the mechanisms involved are poorly understood. Unexpectedly, members of the proton-assisted amino-acid transporter (PAT or SLC36) family emerged from in vivo genetic screens in Drosophila as transporters with uniquely potent effects on mTORC1-mediated growth. In this study, we show the two human PATs that are widely expressed in normal tissues and cancer cell lines, namely PAT1 and PAT4, behave similarly to fly PATs when expressed in Drosophila. Small interfering RNA knockdown shows that these molecules are required for the activation of mTORC1 targets and for proliferation in human MCF-7 breast cancer and HEK-293 embryonic kidney cell lines. Furthermore, activation of mTORC1 in starved HEK-293 cells stimulated by amino acids requires PAT1 and PAT4, and is elevated in PAT1-overexpressing cells. Importantly, in HEK-293 cells, PAT1 is highly concentrated in intracellular compartments, including endosomes, wherein mTOR shuttles upon aminoacid stimulation. Therefore our data are consistent with a model in which PATs modulate the activity of mTORC1 not by transporting amino acids into the cell but by modulating the intracellular response to amino acids.
Introduction
The target of rapamycin complex 1 (TORC1) signalling cascade is an evolutionarily ancient nutrient-sensitive pathway, originally identified in yeast and subsequently shown to be conserved in higher eukaryotes (Kunz et al., 1993; Wullschleger et al., 2006) . TOR, a central component of the TORC1 complex, is a serine-threonine kinase that controls cell growth by regulating several molecules involved in protein translation, including p70 S6-kinase (S6K1), its ribosomal target protein S6, and the inhibitor of translational initiation, 4E-binding protein (4E-BP1; Hietakangas and Cohen, 2009 ). TORC1 also inhibits autophagy (Chang et al., 2009) . Mammalian TORC1 (mTORC1) activity is controlled by oxygen and energy levels, and by extracellular nutrients, in particular amino acids, which are taken up by cells and sensed by a currently unknown intracellular mechanism (Beugnet et al., 2003; Avruch et al., 2009) .
Studies in Drosophila have shown an important role for the phosphoinositide3-kinase (PI3K)/Akt (or protein kinase B) signalling cassette in cell growth control (Goberdhan and Wilson, 2003) . As PI3K/Akt signalling is hyperactivated in the majority of cancers, these findings have highlighted the importance of misregulated cell growth in human tumourigenesis (Brugge et al., 2007; Yuan and Cantley, 2008) . Work in mammals and invertebrates has shown that PI3K/Akt signalling is critically involved in a range of other physiologically important processes, such as ageing (Toivonen and Partridge, 2009) , and that its misregulation is an important factor in several other major human diseases, such as type II diabetes and certain neurodegenerative disorders (Goberdhan and Wilson, 2003; Kim and Mak, 2006; Reynolds et al., 2007) .
Studies in flies have also been instrumental in demonstrating a link between PI3K/Akt signalling and TORC1 (Goberdhan and Wilson, 2003; Hafen, 2004) . TORC1 is activated by the G-protein Rheb (Ras homologue enriched in the brain). This molecule is inhibited by the GAP (GTPase-activating protein) activity of the Tuberous Sclerosis TSC1/TSC2 complex. TSC1/TSC2 can itself be blocked by activated Akt, leading to de-repression of Rheb and activation of TORC1. This link highlighted the importance of mTORC1 signalling in cancer (Guertin and Sabatini, 2007) , particularly in the growth-regulatory control of protein synthesis. Indeed, rapamycin analogues have recently been approved by the Food and Drug Administration for the treatment of patients with advanced renal cell carcinoma (Hudes et al., 2007; Atkins et al., 2009) .
The mechanisms by which mTORC1 is regulated by amino acids remain controversial (Reynolds et al., 2007; Avruch et al., 2009) . As tumour cells can be exposed to conditions in which growth factors, nutrients and oxygen are depleted during cancer progression (Hsu and Sabatini, 2008; Luo et al., 2009) , understanding how amino acids control mTORC1 and how these mechanisms might be altered in tumour cells is an important goal in cancer research, particularly as it might highlight 'sensors' of amino acids that could represent selective drug targets for manipulating mTORC1 signalling (Ganapathy et al., 2009; Hundal and Taylor, 2009 ).
Studies in cell culture have suggested a role for several amino-acid transporters (AATs), including the solutelinked carrier (SLC)1A5 glutamine transporter (otherwise known as ASCT2; alanine-, serine-, cysteine-preferring transporter; Fuchs and Bode, 2005; Nicklin et al., 2009) , the heterodimeric CD98 (SLC7A5/SLC3A2) bidirectional amino-acid exchanger (Nicklin et al., 2009 ) and the sodium-coupled neutral AAT 2 (SNAT2, a member of the SLC38 family; Hundal and Taylor, 2009 ) in aminoacid-dependent mTORC1 activation. In those cases in which the mechanism has been characterized, these transporters are involved in bringing essential amino acids (EAAs) that activate mTORC1, in particular leucine, into the cell (Nicklin et al., 2009) . A number of genes have also been implicated in the process of intracellular nutrient sensing (reviewed in Avruch et al., 2009) , such as MAP4K3 (Findlay et al., 2007) , Vps34 (Byfield et al., 2005; Nobukuni et al., 2005) and the RAG GTPases (Kim et al., 2008; Sancak et al., 2008) . Studies of RAG function led to the proposal that mTORC1 can be activated by amino acids through shuttling to late endosomal compartments (Sancak et al., 2008) . However, the precise mechanisms involved and the intracellular amino-acid sensor remain undiscovered. Furthermore, to date, only the RAGs have been shown to specifically modulate mTORC1 signalling in vivo, using genetic approaches in Drosophila (Kim et al., 2008) .
We used an alternative in vivo approach to dissect the role of AATs in TORC1 regulation, testing the growth effects of overexpressing and mutating AATs, under otherwise normal physiological conditions in flies. This screen identified a completely different set of AATs, the proton-assisted AAT (PAT or SLC36) family, as being uniquely potent transporters in the cell-autonomous regulation of growth and TORC1 signalling (Goberdhan et al., 2005) . PATs were previously identified in mammals as proton-coupled AATs located on the surface of lysosomes (Sagne´et al., 2001 ) and endosomes (Rubio-Alliaga et al., 2004) , as well as on the plasma membrane (Boll et al., 2002; Chen et al., 2003) , suggesting that unlike other putative mTORC1-regulatory AATs, they could act through an intracellular mechanism. However, until now, it has not been clear whether mammalian PATs can promote growth.
In this study, we show that the two ubiquitously expressed human PATs, PAT1 and PAT4, have growthregulatory activity when expressed in flies and display genetic interactions consistent with a role in mTORC1 signalling. Using a small interfering RNA (siRNA) knockdown strategy, we find that reducing the levels of these molecules strongly inhibits cell proliferation and mTORC1 signalling in human MCF-7 breast cancer cells and HEK-293 embryonic kidney cells. Remarkably, PAT1 and PAT4 are required in starved HEK-293 cells for the normal rapid response of mTORC1 to amino-acid addition, even though PAT1 is located intracellularly. Furthermore, overexpression of PAT1 can stimulate this response. We conclude that PATs are important conserved regulators of amino-acid-dependent TORC1 activation and propose that they may perform this function by participating in intracellular amino-acid sensing.
Results
PAT1 and PAT4 are highly expressed in a wide range of human cancer cell lines and normal tissues In contrast to the 11 PATs predicted in the fly genome, there are only 4 PATs in mammals. The tissue distribution of these molecules and their mRNAs has been characterized in a number of species (Bermingham and Pennington, 2004) . These studies, which include quantitative-reverse transcriptase-PCR and northern blot analysis in humans (Nishimura and Naito, 2005) , have indicated that although PAT1 and PAT4 are both expressed in most or all tissues, the other human PATs, namely PAT2 and PAT3, are expressed in a limited range of cell types.
We analysed PAT mRNA levels in a number of human cancer cell lines derived from different tissues using quantitative-reverse transcriptase-PCR, comparing expression levels with those of the abundantly expressed hypoxanthine-guanine phosphoribosyl transferase (HPRT1) housekeeping gene (Table 1) . Consistent with studies in normal human tissues, PAT1 and PAT4 are expressed at moderate to high levels in all lines tested (5-130% of PAT transporters regulate amino-acid/mTORC1-mediated growth S Heublein et al HPRT1 levels). There was no detectable expression of PAT2 or PAT3 (data not shown). Different cell lines derived from the same tissue showed up to 10-fold differences in PAT1 and PAT4 expression (for example, PAT4 in HCT116 and DLD1 colon cancer lines). cDNAs derived from several normal tissues showed expression levels broadly comparable with cancer cell lines from the same tissue. On the basis of their ubiquitous expression, we concluded that PAT1 and PAT4 are the most likely PAT transporters to be involved in the global regulation of growth and proliferation.
Human PAT1 and PAT4 have similar properties to Drosophila PATs when expressed in flies Overexpression of genes in post-mitotic cells of the developing fly eye using the GAL4/UAS system (Brand and Perrimon, 1993) provides a sensitive means of screening for genes that regulate growth, and showed that Drosophila PATs are growth activators (Goberdhan et al., 2005) . To determine whether human PATs can promote growth in vivo, we generated transgenic fly lines in which human PAT1 or PAT4 gene expression can be controlled by GAL4. Expression of PAT1 or PAT4 in the differentiating fly eye under the control of the GMR-GAL4 driver induced modest levels of overgrowth similar to the fly PAT transporter path (Figures 1a-d ).
We previously found that co-expression in the differentiating eye of fly PATs or other growth-promoting TORC1-activating proteins, such as Rheb and S6K1, with the transcription factor FOXO, enhances the characteristic FOXO-induced apoptotic phenotype, an effect not observed with other TORC1-independent growth regulators (Goberdhan et al., 2005) . In flies, TORC1 signalling interferes with the activation of Akt, a key negative regulator of FOXO, through a negative feedback mechanism (Radimerski et al., 2002a, b) , providing an explanation for this characteristic PAT/FOXO genetic interaction. Co-expression of PAT1 or PAT4 with foxo enhanced the FOXO-induced reduced eye phenotype in a similar manner to path (Figures 1e-h ). Therefore, both Drosophila and human PATs promote growth and genetically act like TORC1 regulators in vivo, at least in the fly system.
PAT1 and PAT4 are essential for proliferation in MCF-7 breast cancer cells
The roles of PAT1 and PAT4 in the regulation of tumour cell proliferation were tested in the human MCF-7 breast cancer cell line. The PI3K/Akt signalling cassette is hyperactivated in these cells, because they carry an activating mutation in the PI3K family member PI3KCA (Hollestelle et al., 2007) . PAT1 and PAT4 mRNAs were knocked down using three independent siRNAs for each transcript to control for off-target effects. Cells were cultured for 120 h and their proliferation was assessed by counting the cells blind in a randomized manner. Counts for PAT knockdowns were compared with cells that were untreated, treated with transfectant only or transfected with a scrambled siRNA sequence. In further experiments, three independent mTOR siRNAs were used to test the effects of reducing mTOR-dependent signalling in these cells. Quantitative-reverse transcriptase-PCR showed that knockdown of PAT1, PAT4 and , using GMR-GAL4 is most clearly seen at the ventro-posterior edge of the eye (arrow in e). It is enhanced by co-overexpression of both fly and human PAT transporters (f-h). Scale bar is 100 mm and applies to all panels. Ommatidial size measurements shown at the bottom of panels a-d, mean ± s.d. relative to control; *Po0.001, n ¼ 6.
PAT transporters regulate amino-acid/mTORC1-mediated growth S Heublein et al mTOR produced 60-90% reductions in levels of the targeted transcripts and that this was achieved within 24 h of transfection (Supplementary Figure 1) .
mTOR, PAT1 and PAT4 siRNAs all had similar effects on cell proliferation in these experiments ( Figure 2 ). Compared with controls, cell amplification over the 120-h time course was reduced by >75%. All knockdown samples contained similar numbers of dead cells compared with controls, as assessed by Trypan blue staining (generally o10% of cells were non-viable; Supplementary Table 1), suggesting that the changes in cell number were not primarily due to elevated cell death. Furthermore, there was no significant increase in the total numbers of detached and dead cells in the culture medium (Supplementary Table 1 ). There were also no obvious differences in the morphology of the cells (data not shown). Simultaneous knockdown of both PAT1 and PAT4 using the most effective siRNAs for each of these genes, si159 and si437, had no significant additional effect on MCF-7 cell number. We conclude that both PAT1 and PAT4 are required to promote the proliferation of MCF-7 cells under normal culture conditions. PAT1 and PAT4 modulate mTORC1 signalling in MCF-7 breast cancer cells To test whether PAT1 and PAT4 modulate mTORC1 activity in human cells, protein extracts from knockdown MCF-7 cells were analysed by western blotting using antisera raised against phosphorylated forms of multiple mTORC1 signalling targets, namely Phospho-Thr-389-S6K1, Phospho-Ser-240/244-S6 and Phospho-Ser-65-4E-BP1. As expected, mTOR knockdown strongly reduced the levels of phosphorylated S6K1 and 4E-BP1 compared with controls (Figures 3a  and b) . Both PAT1 and PAT4 knockdown cells also showed reduced phosphorylation of these mTORC1 targets. By contrast, these treatments did not alter PI3K/Akt signalling, as judged by staining with antiPhospho-FoxO1/FoxO3a antiserum. Therefore, the inhibition of proliferation caused by decreased expression of PAT transporters is presumably at least partly explained by a reduction in mTORC1 signalling. Coupled with our in vivo data in flies, these experiments demonstrate that PAT transporters have an evolutionarily conserved role in regulating mTORC1 signalling.
PAT1 and PAT4 modulate the response of mTORC1 to amino acids in human embryonic kidney HEK-293 cells The identification of PATs as regulators of mTORC1 signalling was initially unexpected, because mammalian
Figure 2 PAT1 and PAT4 are both required for normal proliferation of MCF-7 breast cancer cells. The proliferation of MCF-7 breast cancer cells after transfection with siRNAs for mTOR (si825, si826 and si827; a), PAT1 (si158, si159 and si160; b) and PAT4 (si435, si436 and si437; c) was compared with control cells treated with a scrambled siRNA control (sc), lipofectamine only (lp) and non-transfected (nt). A combination of the most effective PAT1 and PAT4 siRNAs did not reduce cell number further (panel b). Bar chart (d) shows cell number at 120 h for samples treated with the most effective siRNAs for mTOR (si827), PAT1 (si159) and PAT4 (si437) normalized to lp control. Error bars represent s.e.m. *Po0.0002: reduced versus lp control. All measurements were made on triplicate samples and the experiment was repeated three times with similar results.
PAT transporters regulate amino-acid/mTORC1-mediated growth S Heublein et al PATs frequently localize not at the cell surface, but in the endosomal and lysosomal compartments within cells (Sagne´et al., 2001; Wreden et al., 2003; Rubio-Alliaga et al., 2004) . However, Sancak et al. (2008) have found that mTOR is translocated to late endosomes upon amino-acid stimulation in HEK-293 cells, suggesting that mTORC1 activation may involve an amino-aciddependent event in this compartment. Staining of MCF-7 and HEK-293 cells with a rabbit antiserum against PAT1 (Wreden et al., 2003) showed that PAT1 is located intracellularly within vesicular structures that are concentrated around the nucleus (Figures 4a and b,  respectively) . HEK-293 cells stably overexpressing PAT1 also showed a similar, but more intense, perinuclear vesicular pattern, confirming the specificity of the antibody staining (Figure 4c ). Although most of the antibodies previously used to study subcellular localization of mTORC1 signalling in these cells were also generated in rabbit (Sancak et al., 2008) , we used a co-transfected Rheb-GFP (green fluorescent protein) construct (Buerger et al., 2006) , which marks mTORC1-activating Rheb and is located in the cytoplasm around late endosomes, primarily at one side of the nucleus in HEK-293 cells (Sancak et al., 2008) . It frequently localized directly adjacent to or surrounded the PAT1 protein (Figures 4d and e) , indicating that as in other cell types, PAT1 is at least partly localized to endosomal structures.
Knockdown of mTOR, PAT1 and PAT4 in HEK-293 cells significantly reduced cell number after 72 h of culture (Figures 4f-i) . We used a different more transient transfection protocol for knockdown in these experiments to facilitate subsequent analysis. As a result, PAT transcript levels were less strongly decreased than in MCF-7 cells (compare Supplementary Figures 1  and 2 ), but western analysis with anti-mTOR and anti-PAT1 antibodies confirmed that protein levels were strongly reduced by the knockdown procedure (Supplementary Figures 2d and e) . Again, there was no evidence for increased levels of dead cells in knockdown samples (Supplementary Table 2 ) and o1% of cells detached from the culture well, indicating that the reduction in cell number caused by either PAT or mTOR knockdown was primarily caused by decreased proliferation. Although we did not specifically study the effect of PAT and mTOR depletion on growth, total protein and RNA levels extracted from HEK-293 knockdown cells were typically reduced relative to controls (Supplementary Table 3 ), suggesting that the net growth of these cells is also inhibited.
mTOR, PAT1 and PAT4 knockdown all significantly reduced levels of phosphorylated S6K1, S6 and 4E-BP1, unlike the scrambled siRNA and MATra-treated controls ( Figure 5 ), but exerted a much more subtle effect on PI3K/Akt signalling, as judged by staining with antiPhospho-FoxO1/FoxO3a antiserum. Phosphorylation of Akt at Ser-473, which is mediated by the mTORcontaining mTORC2 complex, was unaffected, indicating that mTORC2 and PI3K/Akt signalling is not strongly modulated by mTOR or PAT knockdown under these conditions.
To test whether PATs are specifically involved in modulating the sensitivity of mTORC1 to amino acids, we starved normal and knockdown cells of serum and nutrients for 50 min after 72 h of culture, then added back amino acids for 30 min, before assessing phosphorylation of mTORC1 targets (Sancak et al., 2008) . Knockdown of PAT1 and PAT4, as well as mTOR, strongly reduced amino-acid-dependent mTORC1 signalling (Figures 6a-d) , but not mTORC2 signalling, as judged by Akt phosphorylation. In addition, a stable cell line overexpressing PAT1 (Figure 4c ), which proliferates more rapidly than cells transfected with empty vector (Figure 6f ), showed an enhanced response to amino-acids without affecting basal signalling in amino-acid-starved cells (Figure 6e ), strongly suggesting that PATs do not merely have a permissive role in this process. We conclude that PATs are important intracellular regulators of TORC1, which modulate the sensitivity of this complex to amino acids.
Discussion
We have previously identified PAT AATs as uniquely potent AATs in the in vivo regulation of TORC1-mediated Figure 3 PAT1 and PAT4 modulate the activity of the mTORC1 signalling cascade in MCF-7 breast cancer cells. Lysates from MCF-7 cells grown in medium containing 10% serum treated for 120 h with siRNA against PAT1 (si158, si159 and si160), PAT4 (si435, si436 and si437) and mTOR (si825) were compared with control lysates from cells treated with a scrambled siRNA (sc) or lipofectamine only (lp) by probing with anti-Phospho-T389-p70 S6K1 (P-T389-S6K1) and anti-Phospho-T24-FoxO1/T32-FoxO3a (P-FoxO1/3a; a), anti-Phospho-S240/244-S6 (P-S240/244-S6) and anti-Phospho-S65-4E-BP1 (P-S65-4E-BP1; b), as well as nonPhospho-specific antisera against S6K1 and 4E-BP1, and an antia-tubulin antibody to confirm equal loading. All experiments were repeated at least three times with similar results.
PAT transporters regulate amino-acid/mTORC1-mediated growth S Heublein et al Figure 4 PAT1 is located inside MCF-7 and HEK-293 cells from where it regulates cell proliferation. An antiserum against human PAT1 reveals a cytoplasmic localization of endogenous PAT1 protein in both MCF-7 (a; a 0 ¼ phalloidin; a 00 ¼ merge) and HEK-293 (b) cells. HEK-293 cells overexpressing PAT1 produce a much stronger signal with this antibody (c; the detection gain is reduced compared with that in panel b in this confocal image), but the protein distribution is very similar to the endogenous protein pattern. PAT1-containing structures are frequently surrounded by (top arrow), overlapping (lower arrows) or adjacent to regions containing a Rheb-GFP fusion protein, which was previously shown to reside around late endosomal compartments in HEK-293 cells (see low and high magnification views in d and e, respectively: d, e ¼ endogenous PAT1; d 0 , e 0 ¼ Rheb-GFP; d 00 , e 00 ¼ merge). Other PAT1-containing intracellular structures may represent early endosomal or lysosomal compartments, where PATs are located in other cell types. The proliferation of HEK-293 human embryonic kidney cells after transfection with siRNAs for mTOR (si825 and si827; f), PAT1 (si158 and si159; g) and PAT4 (si435 and si437; h) was compared with control cells treated with a scrambled siRNA (sc), or with the MATra reagent only (MATra). Bar chart (i) shows cell number at 72 h for samples treated with each siRNA normalized to sc control. Error bars represent s.e.m. *Po0.01; **Po0.001; reduced versus MATra control. All cell number measurements were made on triplicate samples and the experiment was repeated three times with similar results.
PAT transporters regulate amino-acid/mTORC1-mediated growth S Heublein et al growth in Drosophila. In this study, we show for the first time that two human PATs, namely PAT1 and PAT4, have similar in vivo activities in flies and are also required for proliferation in the human breast cancer cell line MCF-7 and embryonic kidney cell line HEK-293. Furthermore, we show that these PATs are involved in the regulation of mTORC1 signalling and that they are required for amino-acid-dependent activation of this cascade in HEK-293 cells. As PAT1 resides in intracellular compartments within these cells rather than at the cell surface, we propose that the PATs are likely to act through a novel aspect of amino-acid sensing that does not involve simple transport of nutrients across the plasma membrane.
Knockdown of PAT1 or PAT4 produces non-redundant inhibition of cell proliferation and mTORC1 signalling The presence of 4 mammalian PATs versus 11 predicted PATs in the fly facilitated genetic analysis in human cells. Knockdown of PAT1 or PAT4 produced a strong inhibition of proliferation in MCF-7 and HEK-293 cell lines, and in HEK-293 cells, we also showed a clear reduction in total RNA and protein, suggesting that growth is also affected. Multiple siRNAs for each gene produced 55-90% reductions in mRNA levels and typically more than a 60% decrease in cell amplification. Cell survival was not significantly affected, suggesting that blocking PAT activity is cytostatic rather than cytotoxic. Knockdown of mTOR produced similar effects on cell number without affecting the number of dying cells.
Several lines of evidence indicate that the pro-proliferative properties of PAT1 and PAT4 are at least partly mediated through mTORC1. First, these molecules behave similarly to the Drosophila PATs and also other molecules in the mTORC1 signalling cascade in a FOXO-dependent genetic interaction screen in flies (Goberdhan et al., 2005) . Second, in MCF-7 and HEK-293 cells, knockdown of either PAT1 or PAT4 reduces the phosphorylation of the mTORC1 targets S6K1, S6 and 4E-BP1, but does not affect mTORC2 or PI3K/Akt signalling. Third, PATs are important in determining the sensitivity of mTORC1 to amino acids under growth factor-deficient conditions, highlighting a specific role for these transporters in this process. Furthermore, elevated expression of PAT1 increases the sensitivity of mTORC1 to amino acids, strongly supporting a modulatory role for PAT1 in mTORC1's response.
We were surprised to find that both PAT1 and PAT4 knockdown had similar effects on proliferation, and that reducing levels of both genes simultaneously in MCF-7 cells had no further inhibitory action. One possible Lysates from HEK-293 cells grown in medium containing 10% serum for 72 h after transfection with siRNAs against PAT1 (si158 and si159), PAT4 (si435 and si437) and mTOR (si825 and si826) were compared with control lysates from cells treated with a scrambled siRNA (sc) or with the magnet-assisted transfection protocol without siRNA (MATra). Blots were probed with anti-Phospho-Thr-389-p70 S6K1 (P-T389-S6K1), anti-Phospho-Ser-240/244-S6 (P-S240/244-S6), anti-Phospho-S65-4E-BP1 (P-S65-4E-BP1), anti-Phospho-T24-FoxO1/T32-FoxO3a (P-FoxO1/3a), anti-Phospho-S473-Akt (P-S473-Akt) antibodies, non-Phospho-specific antisera against S6K1, S6 and 4E-BP1 and an anti-a-tubulin antibody to confirm equal loading. All experiments were repeated at least three times with similar results. Intensity measurements made from blots produced in three independent experiments reveal significant reduction in S6K1 (b), S6 (c) and 4E-BP1 (d) activation in response to PAT1, PAT4 and mTOR knockdown. *Po0.5; **Po0.001.
PAT transporters regulate amino-acid/mTORC1-mediated growth S Heublein et al Figure 6 PAT1 and PAT4 are required for normal activation of the mTORC1 signalling cascade by amino acids in starved HEK-293 cells. (a) HEK-293 cells were grown in medium containing 10% serum for 72 h after transfection with siRNA against PAT1 (si158 and si159), PAT4 (si435 and si437), mTOR (si825 and si826), a scrambled siRNA (sc) or after exposure to MATraA without siRNA (MATra). They were starved of serum and amino acids for 50 min and then exposed to amino acids for 30 min. Extracts from these cells and cells that were not exposed to amino acids after starvation were analysed by western blot probed with anti-Phospho-Thr-389-p70 S6K1 (P-T389-S6K1), anti-Phospho-Ser-240/244-S6 (P-S240/244-S6), anti-Phospho-Ser-65-4E-BP1 (P-S65-4E-BP1), antiPhospho-Ser-473-Akt (P-S473-Akt) antibodies, non-Phospho-specific antisera against S6K1, S6 and 4E-BP1 and an anti-a-tubulin antibody to confirm equal loading. All experiments were repeated at least three times with similar results. Intensity measurements made from blots produced in three independent experiments reveal significant reduction in S6K1 (b), S6 (c) and 4E-BP1 (d) activation in response to PAT1, PAT4 and mTOR knockdown. *Po0.05; **Po0.001. (e) HEK-293 cells stably transfected with empty vector and a PAT1 overexpression vector were grown in medium containing 10% serum for 72 h, starved of serum and amino acids. Cultures were then exposed either to medium containing amino acids or to starvation medium for a further 30 min. Extracts from these cells were analysed by western blot with the antibodies described above. All experiments were repeated at least three times with similar results.
(f) The proliferation of PAT1-overexpressing cells was compared with non-overexpressing cells over a 48-h time course (n ¼ 6). *Po0.001, proliferation significantly greater than non-expressing cells.
explanation for the lack of redundancy is that PAT1 and PAT4 act together to regulate mTORC1 activity. Indeed, the functional forms of several other AATs and peptide transporters appear to be multimeric, for example, CD98 (Deve´s and Boyd, 2000) and PepT1 (Panitsas et al., 2006) . Alternatively, PAT1 and PAT4 may have distinct roles in mTORC1 control.
Regulation of mTORC1 signalling by PAT transporters Studies in cell culture have highlighted several cell-surface AATs as putative mTORC1 activators (Ganapathy et al., 2009; Hundal and Taylor, 2009; Nicklin et al., 2009) . A critical observation that has shaped this work is that, intracellular leucine and other EAAs can act as potent activators of mTORC1 (Beugnet et al., 2003) and that in Xenopus oocytes, changes in intracellular leucine alter mTORC1 activity (Christie et al., 2002) . Therefore, these mTORC1-regulatory transporter systems are believed to work by modulating intracellular leucine and EAA levels through transport across the plasma membrane (Nicklin et al., 2009) . However, the downstream leucine/EAA sensor remains to be identified. In our in vivo genetic screen for AATs that regulate growth and TOR signalling (Goberdhan et al., 2005) , we had expected to identify other cell-surface AATs that bring amino acids into the cell. However, several lines of evidence suggest that this is not the primary role of the PATs. First, in HEK-293 cells, wherein we have shown a clear role for PATs in amino-acid-dependent stimulation of mTORC1, PAT1 is located intracellularly (Figure 4b ). PAT1 is also found in the endosomes of HeLa cells (Wreden et al., 2003) , which we have found require PATs for normal proliferation (data not shown), and in MCF-7 cells (Figure 4a ), suggesting that this may be a common subcellular distribution in rapidly dividing cells in culture. Second, the proton-assisted mechanism used by PAT transporters is consistent with a role in endosomal and lysosomal, not cell surface, transport . Third, there is currently no evidence that PAT1 acts as a transporter for leucine or mTORC1-activating EAAs with alanine, proline and histidine being its characterized amino-acid substrates . However, as PAT4 remains an orphan transporter of unknown subcellular localization, we cannot eliminate the possibility that this molecule does have a cell-surface function in mTORC1 regulation.
Our data are more consistent with a model in which intracellular PATs alter the sensitivity of mTORC1 to amino acids. Recent studies in HEK-293 cells have shown that in the presence of amino acids, cytoplasmically dispersed mTOR is relocated to late endosomal compartments around which Rheb accumulates (Sancak et al., 2008) , suggesting that some aspects of the aminoacid-sensing mechanism of mTORC1 involve endosomal signalling (Cohen and Hall, 2009) . Although PATs could have a role in any aspect of transmitting the amino-acid signal from the cortical cytoplasm to mTORC1, the endosomal location of these transporters in many cell types and their abilities to interact directly Figure 7 A model to explain the effects of PATs on mTORC1 signalling and proliferation. We have shown that PATs modulate the response of mTORC1 to extracellular amino acids in HEK-293 cells, even though one of the critical PATs in this process, PAT1, is largely intracellular. We propose that these intracellular PATs are likely to affect mTORC1 signalling in late endosomes to which cytoplasmic mTOR is shuttled upon amino-acid stimulation. They may act through a transport-dependent or transceptor mechanism, forming a complex with other mTOR-regulatory proteins, or they may be components of one of a series of endosomal complexes involved in this process. Cytoplasmic leucine, which activates S6K1, may bind to the cytoplasmic face of the PATs to enhance their ability to activate mTORC1. Rag GTPases are required to shuttle mTOR to Rheb-containing endosomal compartments upon amino-acid stimulation, but evidence in yeast suggests they may also bind to amino-acid transporters and promote their shuttling. Rag-dependent shuttling of PATs to the endosomes may therefore be a critical aspect of mTOR regulation.
PAT transporters regulate amino-acid/mTORC1-mediated growth S Heublein et al with amino acids lead us to favour a model in which PATs participate in the intracellular amino-acid-sensing mechanism ( Figure 7 ). PATs may interact either directly or indirectly with endosomal mTORC1 to control the response to amino acids. This activity could involve amino-acid transport from the endosomal lumen or a signalling mechanism, as even PATs with low aminoacid-transport capacity can promote growth in flies, leading to the suggestion that they can act as so-called transceptors (Goberdhan et al., 2005) . As the activity of transceptors can be affected by the concentration of substrate-like molecules on their outer (in this case cytoplasmic) face (Hundal and Taylor, 2009 ), PATs could act directly as sensors for cytoplasmic leucine and EAAs (Figure 7 ). Alternatively, they may merely provide an input to another molecule that acts as the amino-acid sensor for mTORC1 and is responsive to PAT activity and cytoplasmic leucine/EAAs. If PATs are direct sensors of amino acids, this would provide an important functional link between these transporters and cell-surface AATs that modulate mTORC1 activity by altering cytoplasmic amino-acid levels (Zinzalla and Hall, 2008; Goberdhan et al., 2009 ). The recent identification of the RAGs as key mediators of aminoacid-dependent mTORC1 activation (Sancak et al., 2008 ) is of particular interest in this regard, because the orthologues of these molecules in yeast have been implicated in shuttling AATs to their appropriate subcellular compartment (Gao and Kaiser, 2006) . It will now be important to develop tools to establish the precise localization of PATs in the cell, to determine whether they modulate mTORC1 activity by direct or indirect interaction with mTORC1 signalling components, and to establish how they are shuttled around the cell. Ultimately, understanding the mechanism of PAT action may suggest new strategies to modulate mTORC1 activity in cancer and other human diseases in which this pathway is misregulated.
Materials and methods
Cell culture and siRNA transfection conditions for MCF-7 cells MCF-7 cells were typically cultured in 24-well plates (well diameter 1.88 cm 2 ) at seeding densities of 2.5 Â 10 5 per well in medium containing 10% fetal bovine serum (Gibco Invitrogen, Paisley, UK). They were transfected 24 h after plating, when they were B30% confluent. Transfections were performed using lipofectamine RNAimax (Invitrogen) following the manufacturer's instructions with all dilutions carried out in serumreduced optiMEM medium (Invitrogen). Cells were incubated with the siRNA complex over a time course of 120 h.
Cell culture and siRNA transfection conditions for HEK-293 cells HEK-293 cells were cultured in 6-, 12-or 24-well plates at seeding densities of 3.0 Â 10 5 , 1.2 Â 10 5 or 0.6 Â 10 5 cells per well, respectively, in MEM (Minimum Essential Medium Eagle; Sigma-Aldrich, Poole, UK) containing 10% fetal bovine serum (Gibco Invitrogen), 1 Â MEM-NEAA (SigmaAldrich) and 4 mM L-glutamine (Sigma-Aldrich). They were transfected 24 h after plating, when they were B40% confluent. Transfections were performed using the MATraA magnet-assisted transfection protocol (IBA BioTAGnology, Go¨ttingen, Germany) following the manufacturer's instructions with all dilutions carried out in serum-reduced optiMEM medium (Invitrogen). Cells were incubated with the siRNA complex over a time course of 72 h.
Cell counts
For cell counts from each well, cells in the medium and attached cells were separately harvested and then counted in triplicate using a haemocytometer (improved Neubauer model 2007; Sigma-Aldrich) in a randomized, blind manner. Cell viability was measured using Trypan blue. In the case of MCF-7 cells, the remaining cells from the triplicate wells were pooled and pelleted by centrifugation for protein analysis. HEK-293 lysates were collected from separate wells.
Amino-acid starvation Three days after transfection, normal medium was removed from the culture plates. Cells were rinsed once with aminoacid-free RPMI-1640 medium (US Biological, Swampscott, MA, USA). Cells were starved for 50 min in the amino-acidfree medium (at 37 1C, 5% CO 2 ) and then stimulated with amino acids for 30 min. A 50 Â RPMI amino-acid solution (Sigma-Aldrich) was added to the starvation medium to give a final amino-acid concentration equivalent to RPMI-1640 media. After 30 min, medium was discarded, the cells were washed twice with ice-cold phosphate-buffered saline and then lysed in RIPA buffer containing protease and phosphatase inhibitor (Sigma-Aldrich) for 30 min. Lysates were cleared by centrifugation (13 000 r.p.m., 10 min in a microcentrifuge at 4 1C) and either stored at À20 1C or used immediately.
Generation of stable cell line HEK-293 cells were transfected with a pcDNA3.1( þ ) (Invitrogen) construct containing PAT1 under the control of the cytomegalovirus promoter or the empty pcDNA3.1( þ ) vector using FuGene6 (Roche, Welwyn Garden City, UK) as per manufacturer's instructions. Two days after transfection, the cells were split into the selection medium (MEM, 10% fetal bovine serum, 1 Â MEM-NEAA, 4 mM L-glutamine) which contained 800 mg/ml Geneticin (Gibco Invitrogen). The Geneticin concentration (800 mg/ml) used for selection was determined by serial dilution. Medium was replaced every 2-3 days. After 10-15 days, single colonies were picked and expanded in 24-well plates. Expression of the transgene was monitored by immunostaining and western blot analysis.
Statistical analysis
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